These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35438757)

  • 1. Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder.
    Joudrey PJ; Kolak M; Lin Q; Paykin S; Anguiano V; Wang EA
    JAMA Netw Open; 2022 Apr; 5(4):e227028. PubMed ID: 35438757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial and Nonspatial Factors Associated with Access to Medication for Opioid Use Disorder among Pregnant Women in Massachusetts.
    Joshi C; Ho Chui KK; Skeer MR; Stopka TJ
    Subst Use Misuse; 2022; 57(13):1904-1917. PubMed ID: 36219099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails.
    Flanagan Balawajder E; Ducharme L; Taylor BG; Lamuda PA; Kolak M; Friedmann PD; Pollack HA; Schneider JA
    JAMA Netw Open; 2024 Sep; 7(9):e2434704. PubMed ID: 39316401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S; Sun L; Vakkalanka JP
    Am J Emerg Med; 2024 Aug; 82():52-56. PubMed ID: 38795424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
    Huhn AS; Hobelmann JG; Strickland JC; Oyler GA; Bergeria CL; Umbricht A; Dunn KE
    JAMA Netw Open; 2020 Feb; 3(2):e1920843. PubMed ID: 32031650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
    Wyse JJ; Shull S; Lindner S; Morasco BJ; Gordon AJ; Carlson KF; Korthuis PT; Ono SS; Liberto JG; Lovejoy TI
    J Gen Intern Med; 2023 Jun; 38(8):1871-1876. PubMed ID: 36690913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
    Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
    JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
    Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
    J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
    Pilarinos A; Bromberg DJ; Karamouzian M
    JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attitudes toward and training in medications for opioid use disorders: a descriptive analysis among employees in the youth legal system and community mental health centers.
    O'Reilly LM; Schwartz K; Brown SA; Dir A; Gillenwater L; Adams Z; Zapolski T; Hulvershorn LA; Aalsma M
    Subst Abuse Treat Prev Policy; 2024 Jun; 19(1):32. PubMed ID: 38907286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.
    Morgan JR; Walley AY; Murphy SM; Chatterjee A; Hadland SE; Barocas J; Linas BP; Assoumou SA
    Drug Alcohol Depend; 2021 Aug; 225():108764. PubMed ID: 34051547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
    Larochelle MR; Bernson D; Land T; Stopka TJ; Wang N; Xuan Z; Bagley SM; Liebschutz JM; Walley AY
    Ann Intern Med; 2018 Aug; 169(3):137-145. PubMed ID: 29913516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-prescribing clinicians' treatment orientations and attitudes toward treatments for opioid use disorder: Rural differences.
    Brown AR; Walters JE; Harmer B; Cates L; Jones AE
    J Subst Use Addict Treat; 2023 Dec; 155():209153. PubMed ID: 37673286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
    Shastry S; Nobel I; Allen LR; Richardson LD; Vidal K; Manini AF
    Am J Emerg Med; 2022 Jan; 51():114-118. PubMed ID: 34735968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinician Willingness to Prescribe Medications for Opioid Use Disorder to Adolescents in Indiana.
    Aalsma MC; Bell LA; Schwartz K; Ouyang F; Kolak M; Monahan PO; Mermelstein SP; Carson I; Hulvershorn LA; Adams ZW
    JAMA Netw Open; 2024 Sep; 7(9):e2435416. PubMed ID: 39320891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geographic variation in availability of opioid treatment programs across U.S. communities.
    Jehan S; Zahnd WE; Wooten NR; Seay KD
    J Addict Dis; 2024; 42(2):136-146. PubMed ID: 36645315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
    Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
    JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
    Sharma A; Kelly SM; Mitchell SG; Gryczynski J; O'Grady KE; Schwartz RP
    Curr Psychiatry Rep; 2017 Jun; 19(6):35. PubMed ID: 28526967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.